Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
Thymogen
Immune & Longevity
Molecular Dossier
- Rank Index: 80
- Status: Research Only
- What does this mean?
- Molecular Structure: MW: 333.35 Da | Formula: C₁₄H₁₅N₃O₅ | CAS: 13250-74-3 | Dipeptide: Glu-Trp
About Thymogen
Thymogen (glutamyl-tryptophan; Glu-Trp) is a synthetic dipeptide developed from thymic extract research at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues. It is among the shortest of the peptide bioregulators, consisting of only two amino acids, yet demonstrates meaningful immunomodulatory activity in both animal models and human clinical trials. Thymogen acts primarily to restore thymus-dependent immune function: it promotes differentiation of T-lymphocyte precursors, increases the CD4+/CD8+ T-cell ratio, enhances natural killer (NK) cell cytotoxicity, and upregulates production of interleukin-2 (IL-2) — the key growth factor for T-cell proliferation. In elderly subjects, where thymic involution has substantially reduced T-cell output, clinical studies demonstrated improved immune reactivity, reduced incidence of infectious disease, and enhanced antibody response to vaccination. The dipeptide is structurally related to the C-terminal sequence of thymopoietin and thymulin, suggesting it may mimic or trigger similar signaling pathways. Clinical use in Russia and Eastern Europe includes treatment of secondary immunodeficiencies, chronic infections, and as adjunct therapy in cancer patients receiving immunosuppressive treatments. Available as nasal spray (intranasal) or injectable formulation. Safety profile is favorable given the simplicity of the molecule and its endogenous amino acid composition. Research interest is growing in the context of immunosenescence — the age-related decline in immune surveillance that contributes to increased cancer incidence and infection vulnerability.
Clinical Focus
Thymic Dipeptide — T-Cell Restoration, Immune Aging, Antiviral Defense
Archival Aliases
Glutamyl-tryptophan, Glu-Trp, TP-1
Frequently Asked Questions
What are the typical research protocols for Thymogen dosing?
Clinical protocols in the Russian literature typically describe intranasal Thymogen at 100 mcg per nostril (200 mcg total) once or twice daily for courses of 5–10 days, repeated seasonally. Injectable protocols range from 50–100 mcg subcutaneously daily for 5–10 days. These are not FDA-approved protocols and originate from Russian clinical registrations. No dose-finding studies have been conducted under Western regulatory standards. The short dipeptide structure and amino acid composition suggest a favorable safety margin, but the optimal human dose has not been established via randomized controlled trials.
How does Thymogen compare to Thymalin?
Thymalin is a polypeptide mixture extracted from calf thymus tissue, containing multiple short peptides with immunomodulatory activity. Thymogen (Glu-Trp) is a synthetic, defined dipeptide developed as a more reproducible, chemically characterized successor. Thymalin's complexity makes batch-to-batch consistency challenging but may provide broader immunomodulatory coverage. Thymogen's single defined structure offers reproducibility and allows more precise mechanism studies. Both originate from the same Khavinson research group and share the goal of restoring thymic-dependent immunity; they are sometimes used in combination protocols targeting different aspects of T-cell aging.
What is the advantage of intranasal versus injectable Thymogen?
Intranasal Thymogen offers a non-invasive administration route with reasonably direct access to the olfactory bulb and potential direct CNS delivery, bypassing the blood-brain barrier. For immune function, the nasal-associated lymphoid tissue (NALT) may also be a direct target. Injectable subcutaneous delivery provides more predictable systemic bioavailability but requires sterile technique. Most human clinical trials used intranasal delivery, making it the better-evidenced route. The dipeptide structure (only 2 amino acids) means oral bioavailability is very low due to gastrointestinal peptidase activity — oral use is not supported.
Who is most likely to benefit from Thymogen research protocols?
The populations showing the most consistent signal in Thymogen research are: (1) Elderly individuals with documented immunosenescence — reduced CD4+ T-cell counts, impaired NK cell function, and poor vaccine response. (2) Patients recovering from severe illness or chemotherapy with secondary immunodeficiency. (3) Individuals with recurrent infections suggesting compromised cellular immunity. (4) Researchers studying thymic biology and T-cell aging. For healthy, immunocompetent younger adults, the benefit is likely minimal given intact thymic function. The compound is most relevant where thymic involution (which begins in the 20s and accelerates with age) has meaningfully impaired T-cell output.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | MW: 333.35 Da | Formula: C₁₄H₁₅N₃O₅ | CAS: 13250-74-3 | Dipeptide: Glu-Trp |
| Primary Pathway | Immune & Longevity |
| Research Phase | Research Only |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-15